{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:47:23Z","timestamp":1761821243143,"version":"3.37.0"},"reference-count":90,"publisher":"Wiley","issue":"s9","license":[{"start":{"date-parts":[[2008,12,5]],"date-time":"2008-12-05T00:00:00Z","timestamp":1228435200000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2008,12]]},"abstract":"<jats:sec><jats:title>PRO\u2014Summary<\/jats:title><jats:p>In the past decade, genotyping has started to help the neurologic practitioner treat patients with three types of epilepsy causing mutations, namely (1)<jats:italic>SCN1A<\/jats:italic>, a sodium channel gene mutated in Dravet\u2019s sporadic severe myoclonic epilepsy of infancy (SMEI and SMEB); (2) laforin (dual specificity protein phosphatase) and malin (ubiquitin E3 ligase) in Lafora progressive myoclonic epilepsy (PME); and (3) cystatin B in Unverricht\u2010Lundborg type of PME. Laforin, malin, and cystatin B are non\u2013ion channel gene mutations that cause PME. Genotyping ensures accurate diagnosis, helps treatment and genetic counseling, psychological and social help for patients and families, and directs families to organizations devoted to finding cures for specific epilepsy diseases. In<jats:italic>SCN1A<\/jats:italic>and cystatin B mutations, treatment with sodium channel blockers (phenytoin, carbamazepine, oxcarbazepine, lamotrigine) should be avoided. Because of early and correct diagnosis by genotyping of<jats:italic>SCN1A<\/jats:italic>mutations, the avoidance of sodium channel blockers, and aggressive treatment of prolonged convulsive status, there is hope that Dravet\u2019s syndrome may not be as severe as observed in all past reports. Genotyping also identifies nonsense mutations in Lafora PME. Nonsense mutations can be corrected by premature stop codon readthrough drugs such as gentamicin. The community practitioner together with epilepsy specialists in PME can work together and acquire gentamicin (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"#b2\">Barton\u2010Davis et\u00a0al., 1999<\/jats:ext-link>) for \u201ccompassionate use\u201d in Lafora PME, a generalized lysosome multiorgan storage disorder that is invariably fatal. In Unverricht\u2010Lundborg PME, new cohorts with genotyped cystatin B mutations have led to the chronic use of antioxidant<jats:italic>N<\/jats:italic>\u2010acetylcysteine and combination valproate clobazam or clonazepam plus antimyoclonic drugs topiramate, zonisamide, piracetam, levetiracetam, or brivaracetam. These cohorts have minimal ataxia and no dementia, questioning whether the syndrome is truly progressive. In conclusion, not only is genotyping a prerequisite in the diagnosis of Dravet\u2019s syndrome and the progressive myoclonus epilepsies, but it also helps us choose the correct antiepileptic drugs to treat seizures in Dravet\u2019s syndrome and Unverricht\u2010Lundborg PME. Genotyping also portends a brighter future, helping us to reassess the true course, severity, and progressive nature of Dravet\u2019s syndrome and Unverricht\u2010Lundborg PME and helping us craft a future curative treatment for Dravet\u2019s syndrome and Lafora disease. Without the genotyping diagnosis of epilepsy causing mutations we are stuck with imprecise diagnosis and symptomatic treatment of seizures.<\/jats:p><\/jats:sec><jats:sec><jats:title>CON\u2014Summary<\/jats:title><jats:p>Genotyping of epilepsy may help to better understand the genetics of epilepsy, to establish an etiology in a patient with epilepsy, to provide genetic counseling, and to confirm a clinical diagnosis. However, critical analysis reveals that genotyping does not contribute to an improved treatment for the patients. In order to improve treatment, genotyping would have to (1) improve our ability to select the drug of choice for a given epilepsy or epileptic syndrome; (2) improve our ability to predict the individual risk of adverse reactions to certain drugs; (3) improve our ability to avoid unnecessary treatments or treatments that could aggravate seizures.<\/jats:p><jats:p>Many example illustrate the lack of impact of genetic information on the treatment outcome: we do not treat Dravet syndrome more successfully since SCN1A testing became available; we do not treat Lafora disease more successfully since testing for laforin and malin became available; we do not need to know the genetic nature of Unverricht\u2010Lundborg disease or test for the cystatin B mutation in order to select or avoid certain drugs; we do not treat Rett syndrome more successfully since MECP2 testing became available; we do not treat JME more successfully since we know its genetic origin; we do not treat autosomal dominant nocturnal frontal lobe epilepsy more successfully since we know its genetic origin and can test for its mutation.<\/jats:p><jats:p>The clinical characteristics as well as the response to treatment of these epilepsy syndromes have been well established before genotyping became available. It can not be argued that genotyping is necessary for establishing a diagnosis or ensure accurate diagnosis. Since not all individuals with given syndromes have been shown to have the corresponding mutation, the clinical diagnosis must have been based on well\u2010established clinical criteria. In addition, the presence or absence of the mutation in a given patient has never been shown to specifically predict the response to any form of treatment, positive or negative. Finally, the appropriate psychological and social help in a given patient will not depend on the identification of a mutation. This does not leave any role for genotyping in epilepsy for the sole reason of improving treatment of the patient. Claiming that the result of genotyping predicts optimal treatment in certain epilepsies is equivalent to stating that genotyping for diabetes has become available and that, based on this breakthrough, insulin can now be selected as the treatment of choice in those who test positive.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1528-1167.2008.01922.x","type":"journal-article","created":{"date-parts":[[2008,12,5]],"date-time":"2008-12-05T18:37:52Z","timestamp":1228502272000},"page":"13-24","source":"Crossref","is-referenced-by-count":31,"title":["Debate: Does genetic information in humans help us treat patients?"],"prefix":"10.1111","volume":"49","author":[{"given":"Antonio V.","family":"Delgado\u2010Escueta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blaise F.D.","family":"Bourgeois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,12,5]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_2_10_2_1","DOI":"10.1038\/sj.ejhg.5201300"},{"doi-asserted-by":"publisher","key":"e_1_2_10_3_1","DOI":"10.1172\/JCI7866"},{"doi-asserted-by":"publisher","key":"e_1_2_10_4_1","DOI":"10.1086\/302593"},{"key":"e_1_2_10_5_1","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/ng0501-46","article-title":"First genetic evidence of GABAA receptor dysfunction in epilepsy: A mutation in the {gamma}2\u2010subunit gene","volume":"28","author":"Baulac S","year":"2001","journal-title":"Nat Genet"},{"doi-asserted-by":"publisher","key":"e_1_2_10_6_1","DOI":"10.1016\/S1474-4422(06)70446-X"},{"doi-asserted-by":"publisher","key":"e_1_2_10_7_1","DOI":"10.1212\/WNL.55.11.1757"},{"doi-asserted-by":"publisher","key":"e_1_2_10_8_1","DOI":"10.1016\/j.molmed.2006.06.001"},{"doi-asserted-by":"publisher","key":"e_1_2_10_9_1","DOI":"10.1212\/WNL.56.10.1424-a"},{"doi-asserted-by":"publisher","key":"e_1_2_10_10_1","DOI":"10.1177\/08830738040190070701"},{"doi-asserted-by":"publisher","key":"e_1_2_10_11_1","DOI":"10.1086\/320609"},{"doi-asserted-by":"publisher","key":"e_1_2_10_12_1","DOI":"10.1164\/ajrccm.163.7.2004001"},{"doi-asserted-by":"publisher","key":"e_1_2_10_13_1","DOI":"10.1111\/j.1528-1167.2007.01153.x"},{"doi-asserted-by":"publisher","key":"e_1_2_10_14_1","DOI":"10.1038\/ng885"},{"doi-asserted-by":"publisher","key":"e_1_2_10_15_1","DOI":"10.1007\/s11910-007-0066-7"},{"doi-asserted-by":"publisher","key":"e_1_2_10_16_1","DOI":"10.1111\/j.1535-7511.2007.00171.x"},{"doi-asserted-by":"publisher","key":"e_1_2_10_17_1","DOI":"10.1093\/hmg\/ddh146"},{"key":"e_1_2_10_18_1","first-page":"75","volume-title":"Epileptic syndromes in infancy, childhood and adolescence","author":"Dravet C","year":"1992"},{"key":"e_1_2_10_19_1","first-page":"71","article-title":"Severe myoclonic epilepsy in infancy: Dravet syndrome","volume":"95","author":"Dravet C","year":"2005","journal-title":"Adv Neurol"},{"key":"e_1_2_10_20_1","first-page":"89","volume-title":"Epileptic syndromes in infancy, childhood and adolescence","author":"Dravet C","year":"2006"},{"doi-asserted-by":"publisher","key":"e_1_2_10_21_1","DOI":"10.1055\/s-2005-865607"},{"doi-asserted-by":"publisher","key":"e_1_2_10_22_1","DOI":"10.1212\/WNL.59.9.1447"},{"doi-asserted-by":"publisher","key":"e_1_2_10_23_1","DOI":"10.1016\/S0140-6736(83)90749-3"},{"doi-asserted-by":"publisher","key":"e_1_2_10_24_1","DOI":"10.1038\/74159"},{"doi-asserted-by":"publisher","key":"e_1_2_10_25_1","DOI":"10.1086\/319524"},{"doi-asserted-by":"publisher","key":"e_1_2_10_26_1","DOI":"10.1586\/14737175.6.12.1789"},{"doi-asserted-by":"publisher","key":"e_1_2_10_27_1","DOI":"10.1016\/j.eplepsyres.2006.01.019"},{"doi-asserted-by":"publisher","key":"e_1_2_10_28_1","DOI":"10.1093\/brain\/awg053"},{"doi-asserted-by":"publisher","key":"e_1_2_10_29_1","DOI":"10.1093\/hmg\/11.11.1263"},{"volume-title":"International Workshop on Progressive Myoclonus Epilepsies","year":"2007","author":"Genton P","key":"e_1_2_10_30_1"},{"key":"e_1_2_10_31_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1684\/j.1950-6945.2000.tb00445.x","article-title":"Antimyoclonic effect of levetiracetam","volume":"2","author":"Genton P","year":"2000","journal-title":"Epileptic Disord"},{"key":"e_1_2_10_32_1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1684\/j.1950-6945.2000.tb00363.x","article-title":"Piracetam and levetiracetam: Close structural similarities but different pharmacological and clinical profiles","volume":"2","author":"Genton P","year":"2000","journal-title":"Epileptic Disord"},{"issue":"1","key":"e_1_2_10_33_1","first-page":"49","article-title":"Piracetam in the treatment of cortical myoclonus","volume":"32","author":"Genton P","year":"1999","journal-title":"Pharmacopsychiatry"},{"doi-asserted-by":"publisher","key":"e_1_2_10_34_1","DOI":"10.1212\/WNL.55.8.1106"},{"key":"e_1_2_10_35_1","first-page":"441","volume-title":"Epileptic Syndromes in Infancy, Childhood and Adolescence","author":"Genton P","year":"2005"},{"doi-asserted-by":"publisher","key":"e_1_2_10_36_1","DOI":"10.1111\/j.1528-1167.2006.00829.x"},{"doi-asserted-by":"publisher","key":"e_1_2_10_37_1","DOI":"10.1212\/01.wnl.0000266666.10404.53"},{"doi-asserted-by":"publisher","key":"e_1_2_10_38_1","DOI":"10.1111\/j.1528-1157.1998.tb05118.x"},{"doi-asserted-by":"publisher","key":"e_1_2_10_39_1","DOI":"10.1111\/j.1528-1157.1998.tb01413.x"},{"doi-asserted-by":"publisher","key":"e_1_2_10_40_1","DOI":"10.1111\/j.0013-9580.2004.43703.x"},{"doi-asserted-by":"publisher","key":"e_1_2_10_41_1","DOI":"10.1093\/brain\/awm002"},{"doi-asserted-by":"publisher","key":"e_1_2_10_42_1","DOI":"10.1212\/WNL.47.5.1264"},{"doi-asserted-by":"publisher","key":"e_1_2_10_43_1","DOI":"10.1212\/01.wnl.0000249312.73155.7d"},{"doi-asserted-by":"publisher","key":"e_1_2_10_44_1","DOI":"10.1111\/j.1528-1167.2007.01422.x"},{"doi-asserted-by":"publisher","key":"e_1_2_10_45_1","DOI":"10.1111\/j.1528-1167.2008.01546.x"},{"doi-asserted-by":"publisher","key":"e_1_2_10_46_1","DOI":"10.1212\/01.WNL.0000129829.31179.5B"},{"doi-asserted-by":"publisher","key":"e_1_2_10_47_1","DOI":"10.1001\/archneur.59.7.1137"},{"doi-asserted-by":"publisher","key":"e_1_2_10_48_1","DOI":"10.1016\/S0896-6974(05)80132-X"},{"doi-asserted-by":"publisher","key":"e_1_2_10_49_1","DOI":"10.1097\/01.mcp.0000141247.22078.46"},{"doi-asserted-by":"publisher","key":"e_1_2_10_50_1","DOI":"10.1038\/ncpneuro0605"},{"doi-asserted-by":"publisher","key":"e_1_2_10_51_1","DOI":"10.1136\/jnnp.64.3.344"},{"doi-asserted-by":"publisher","key":"e_1_2_10_52_1","DOI":"10.1038\/ng0397-298"},{"key":"e_1_2_10_53_1","first-page":"342","article-title":"Identification of mutations in cystatin B, the gene responsible for the Unverricht\u2010Lundborg type of progressive myoclonus epilepsy (EPM1)","volume":"60","author":"Lalioti MD","year":"1997","journal-title":"Am J Hum Genet"},{"doi-asserted-by":"publisher","key":"e_1_2_10_54_1","DOI":"10.1038\/386847a0"},{"doi-asserted-by":"publisher","key":"e_1_2_10_55_1","DOI":"10.1093\/hmg\/10.18.1867"},{"doi-asserted-by":"publisher","key":"e_1_2_10_56_1","DOI":"10.1086\/302768"},{"doi-asserted-by":"publisher","key":"e_1_2_10_57_1","DOI":"10.1111\/j.0013-9580.2004.56902.x"},{"doi-asserted-by":"publisher","key":"e_1_2_10_58_1","DOI":"10.1073\/pnas.0506818102"},{"doi-asserted-by":"publisher","key":"e_1_2_10_59_1","DOI":"10.1111\/j.1528-1167.2007.01122.x"},{"key":"e_1_2_10_60_1","first-page":"307","article-title":"Treatment of myoclonic epilepsies of childhood, adolescence, and adulthood","volume":"95","author":"Medina MT","year":"2005","journal-title":"Adv Neurol"},{"doi-asserted-by":"publisher","key":"e_1_2_10_61_1","DOI":"10.1086\/302621"},{"doi-asserted-by":"publisher","key":"e_1_2_10_62_1","DOI":"10.1002\/humu.20178"},{"doi-asserted-by":"publisher","key":"e_1_2_10_63_1","DOI":"10.1212\/01.WNL.0000069463.41870.2F"},{"doi-asserted-by":"publisher","key":"e_1_2_10_64_1","DOI":"10.1053\/seiz.2000.0466"},{"doi-asserted-by":"publisher","key":"e_1_2_10_65_1","DOI":"10.1111\/j.1440-1819.1989.tb02948.x"},{"doi-asserted-by":"publisher","key":"e_1_2_10_66_1","DOI":"10.1016\/S0387-7604(01)00276-5"},{"key":"e_1_2_10_67_1","first-page":"103","article-title":"Severe myoclonic epilepsy in infancy: Clinical analysis and relation to SCN1A mutations in a Japanese cohort","volume":"95","author":"Oguni H","year":"2005","journal-title":"Adv Neurol"},{"doi-asserted-by":"publisher","key":"e_1_2_10_68_1","DOI":"10.1016\/S1059-1311(97)80009-X"},{"doi-asserted-by":"publisher","key":"e_1_2_10_69_1","DOI":"10.1016\/S0006-291X(02)00617-4"},{"doi-asserted-by":"publisher","key":"e_1_2_10_70_1","DOI":"10.1016\/S0387-7604(03)00038-X"},{"doi-asserted-by":"publisher","key":"e_1_2_10_71_1","DOI":"10.1016\/j.eplepsyres.2007.03.018"},{"doi-asserted-by":"publisher","key":"e_1_2_10_72_1","DOI":"10.1002\/1531-8249(199910)46:4<671::AID-ANA20>3.0.CO;2-5"},{"doi-asserted-by":"publisher","key":"e_1_2_10_73_1","DOI":"10.1126\/science.271.5256.1731"},{"key":"e_1_2_10_74_1","first-page":"15","article-title":"Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results","volume":"22","author":"Politano L","year":"2003","journal-title":"Acta Myol"},{"doi-asserted-by":"publisher","key":"e_1_2_10_75_1","DOI":"10.1165\/rcmb.2001-0004OC"},{"doi-asserted-by":"publisher","key":"e_1_2_10_76_1","DOI":"10.1113\/jphysiol.2005.094326"},{"doi-asserted-by":"publisher","key":"e_1_2_10_77_1","DOI":"10.1093\/brain\/120.3.479"},{"unstructured":"SeinoM HigashiT. (1978)The investigation on a group of secondary generalized epilepsy in childhood with onset in infancy and refractory grand mal. The Ministry of Health and Welfare \u2013 The foundation in commissioning investigation on psychosomatic disorders. The report of investigations in Showa 53 the group of investigation on children\u2019s health and environment pp.79\u201380.","key":"e_1_2_10_78_1"},{"doi-asserted-by":"publisher","key":"e_1_2_10_79_1","DOI":"10.1186\/1741-7015-5-5"},{"doi-asserted-by":"publisher","key":"e_1_2_10_80_1","DOI":"10.1212\/01.wnl.0000265222.24102.db"},{"doi-asserted-by":"publisher","key":"e_1_2_10_81_1","DOI":"10.1016\/j.ajhg.2008.04.020"},{"key":"e_1_2_10_82_1","first-page":"382","article-title":"Lafora disease, a form of progressive myoclonus epilepsy","volume":"15","author":"Van Heycop Ten Ham MW","year":"1974","journal-title":"Handbook of Clinical Neurology"},{"volume-title":"Epilepsy Atlas \u2013 CT and EEG","year":"1983","author":"Wada T","key":"e_1_2_10_83_1"},{"doi-asserted-by":"publisher","key":"e_1_2_10_84_1","DOI":"10.1002\/ana.1023"},{"key":"e_1_2_10_85_1","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/1252","article-title":"Febrile seizures and generalized epilepsy associated with a mutation in the Na+ channel \u03b21 subunit gene SCN1B","volume":"19","author":"Wallace RH","year":"1998","journal-title":"Nat Genet"},{"doi-asserted-by":"publisher","key":"e_1_2_10_86_1","DOI":"10.1038\/ng0501-49"},{"doi-asserted-by":"publisher","key":"e_1_2_10_87_1","DOI":"10.1086\/319516"},{"doi-asserted-by":"publisher","key":"e_1_2_10_88_1","DOI":"10.1212\/01.WNL.0000086379.71183.78"},{"doi-asserted-by":"publisher","key":"e_1_2_10_89_1","DOI":"10.1038\/nature05756"},{"doi-asserted-by":"publisher","key":"e_1_2_10_90_1","DOI":"10.1056\/NEJMoa022170"},{"doi-asserted-by":"publisher","key":"e_1_2_10_91_1","DOI":"10.1016\/S0387-7604(12)80147-1"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1528-1167.2008.01922.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1528-1167.2008.01922.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T18:29:36Z","timestamp":1738780176000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1528-1167.2008.01922.x"}},"subtitle":["PRO\u2014genetic information in humans helps us treat patients\u2028CON\u2014genetic information does not help at all"],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":90,"journal-issue":{"issue":"s9","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["10.1111\/j.1528-1167.2008.01922.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1528-1167.2008.01922.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"type":"print","value":"0013-9580"},{"type":"electronic","value":"1528-1167"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}